Lung Adenocarcinoma In Situ
NCI Definition: A localized non-invasive adenocarcinoma of the lung measuring 3 cm or less. It is characterized by a pure lepidic growth pattern and the lack of stromal, vascular, or pleural invasion. 
Lung adenocarcinoma in situs most frequently harbor alterations in EGFR .
EGFR Mutation are the most common alterations in lung adenocarcinoma in situ .
There is 1 clinical trial for lung adenocarcinoma in situ, of which 1 is open and 0 are completed or closed. Of the trial that contains lung adenocarcinoma in situ as an inclusion criterion, 1 is phase 2 (1 open).
Ipilimumab and nivolumab are the most common interventions in lung adenocarcinoma in situ clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.